Tuhina Neogi MD, PhD

Section Chief of Rheumatology, Rheumatology

Professor, Rheumatology

650 Albany St | (617) 358-9650
Tuhina Neogi
Sections

Rheumatology

Centers

Arthritis & Autoimmune Diseases Research Center

Framingham Heart Study

Evans Center for Interdisciplinary Biomedical Research

Biography

I am a rheumatologist and epidemiologist whose research has focused primarily on risk factors for knee osteoarthritis and gout, pain mechanisms in knee osteoarthritis, as well as methodologic issues of relevance for rheumatic diseases. I have had continuous peer-reviewed foundation and NIH funding since 2003, and have over 300 peer-reviewed publications to date. I am a past chair of the FDA Arthritis Advisory Committee, serve(d) on the boards two international societies: Osteoarthritis Research Society International (OARSI) and Gout, Hyperuricemia, and Crystal-Associated Diseases Network (G-CAN), and on committees for the American College of Rheumatology (ACR) and International Association for the Study Pain (IASP), among others. My work has been recognized with the prestigious 2014 ACR Henry Kunkel Young Investigator Award for outstanding and promising independent contributions to rheumatology research (awarded to no more than one clinical researcher and/or one basic science researcher each year), and the 2022 OARSI Clinical Research Award (in recognition of important contributions to OA research). I have also engaged in developing new classification criteria for a number of rheumatic diseases. In addition to research, clinical work, and teaching, one of my key roles is to mentor trainees and junior faculty in musculoskeletal disease-related research. To that end, I was awarded the 2016 Robert Dawson Evans Research Mentoring Award. I also developed and led the new CTSI Research Career Support Program initiative, PRIME (Pathways to Research Independence and Mentoring Excellence), which aims to support early career mentored researchers to successfully transition to becoming independent researchers.

Expertise includes:
- Osteoarthritis: epidemiology; risk factors; mechanisms of osteoarthritis-related pain; the role of bone in the pathophysiology of osteoarthritis
- Gout: epidemiology; risk factors and triggers for gout attacks; management of gout; consequences of gout and hyperuricemia
- Classification criteria and outcome measures in rheumatic diseases.
- Novel methodology to address challenging epidemiologic issues

Other Positions

Education

Medicine, MD, University of Toronto

Epidemiology, PhD, Boston University School of Public Health

Biochemistry, BS, McMaster University

Publications

Published on 9/22/2025

Degirmenci HB, Peloquin CE, Westerland M, Lodi S, Machado PM, Jafarzadeh SR, Neogi T, Gensler LS, Dubreuil M, Liew JW. Trends in Opioid Prescriptions in Individuals with Axial Spondyloarthritis in the US and UK in the Last Two Decades: Analysis of Electronic Health Records and Insurance Claims Data. Arthritis Care Res (Hoboken). 2025 Sep 22. PMID: 40977482.

Published on 9/5/2025

George N, Liew JW, Wang N, Tilley S, Guermazi A, Lynch J, Lewis C, Torner J, Neogi T. Does hsCRP provide insights into an inflammatory phenotype of knee osteoarthritis? Osteoarthritis Cartilage. 2025 Sep 05. PMID: 40915380.

Published on 8/29/2025

Dalbeth N, Stewart S, Gamble GD, Mihov B, Stamp LK, Haslett J, Taylor WJ, Merriman TR, Tabi-Amponsah AD, Horne A, Neogi T, Pascart T, Andrés M, Peral-Garrido ML, Norkuviene E, Mellado JV, Uhlig T, Sun M, Li C, Petrie KJ. Perceptions about asymptomatic hyperuricemia and views about urate-lowering therapy in people with asymptomatic hyperuricemia. Arthritis Care Res (Hoboken). 2025 Aug 29. PMID: 40884020.

Published on 8/12/2025

Aoyagi K, Wang N, LaValley M, Tilley S, Frey-Law L, Lewis CE, Nevitt M, Neogi T. Longitudinal Trajectories of Pain Sensitization Over Nine Years in People With or at Risk of Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2025 Aug 12. PMID: 40790991.

Published on 8/7/2025

Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, Michaud K, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, O'Dell JR, Mikuls TR. Improvements in Health-Related Quality of Life with Treat-to-Target Urate-Lowering Therapy in Gout: A Post-hoc Analysis of a Randomized Multicenter Trial. Arthritis Care Res (Hoboken). 2025 Aug 07. PMID: 40771143.

Published on 8/5/2025

Kohn S, Sayles H, Helget LN, England BR, Roul P, Newcomb JA, Kramer B, Davis-Karim A, Brophy MT, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, O'Dell JR, Mikuls TR. Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum. 2025 Oct; 74:152800. PMID: 40782426.

Published on 8/4/2025

Helget LN, England BR, Roul P, Sayles H, Neogi T, O'Dell JR, Baker JF, Mikuls TR. Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration. Arthritis Care Res (Hoboken). 2025 Aug 04. PMID: 40757470.

Published on 8/4/2025

Wu Y, Liew JW, Boer JD, Westerland M, LaValley M, Voortman T, Bierma-Zeinstra S, Oei EHG, van Meurs JBJ, Neogi T, Boer CG. Chondrocalcinosis and incident knee osteoarthritis: findings from 2 large prospective cohorts with 20 years of follow-up. Ann Rheum Dis. 2025 Aug 04. PMID: 40764183.

Published on 8/2/2025

Raut RD, Chakraborty AK, Neogi T, Albro M, Snyder B, Schaer TP, Zhang C, Grinstaff MW, Bais MV. A multi-tissue human knee single-cell atlas identifies that osteoarthritis reduces regenerative tissue stem cells while increasing inflammatory pain macrophages. Commun Biol. 2025 Aug 02; 8(1):1146. PMID: 40753276.

Published on 8/1/2025

Jauffret C, Tedeschi SK, Abhishek A, Latourte A, Filippou G, Neogi T, Pascart T. Calcium pyrophosphate crystal deposition: 2025 update to recent epidemiological findings. Curr Opin Rheumatol. 2025 Nov 01; 37(6):437-444. PMID: 40747977.

View full list of 408 publications.